Business - Briefly   

Nihon Pharma launches diabetes drug

NEW DELHI: Ranbaxy Laboratories on Monday said Nihon Pharmaceuticals Industry (NPI), a joint venture between the company and Nippon Chemiphar, has launched its first co-developed product Vogseal tablets in Japan. The product, used for the treatment of diabetes, will be sold in Japan under the Ranbaxy or NPI label and marketed by the field forces of Nippon Chemiphar and NPI, Ranbaxy informed the BSE.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

RBI increases risk weights for real estate, capital market
Global uncertainties under watch, says Y. V. Reddy
EU tightens funds transfer norms
Norms for tea leaf plucking announced
FM supports RBI stance
TVS Motor net dips
SPIC reduces losses
Lucas-TVS venture in Iran
Ashok Leyland Q1 net doubles
Invitation for SSIs
Bharti Tele Q1 net zooms 72 p.c. to Rs. 510 cr.
Sensex gains 47 points
Rupee rebounds against $
Exchange rates
Bullion rates
Notification on derivatives
Air Deccan IPO next year
NPC study team visits Dunlop unit
Progeon centres in U.S., Europe
NBFCs seek more funds from banks
Single window system inaugurated
Ramco's e.Application for SMEs
Travel agents body meet in Singapore
Dr. Reddy's Lab Q1 profit doubles
KLM Royal Dutch to link Hyderabad
3 Global Services deploys Cisco's network
C-COM Corporation introduces new products
Infrastructure Fund from Prudential ICICI
Microsoft launches WGA 1.0 in India
GE sets up corporate growth team
State Bank of Mysore Q1 net drops
Northwest, Air France services to Bangalore
Toyota to concentrate on South
Coffee Day launches new scheme
Course in steel technology
Nihon Pharma launches diabetes drug

Copyright © 2005, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu